Aspen Pharmacare Holdings Ltd. (APNHF)
8.896
0.00 (0.00%)
USD |
OTCM |
Aug 26, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 3.950B |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | 24.77% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | |
| PS Ratio | 1.841 |
| Price to Book Value | -- |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | 0.1220 |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | -- |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | 67.30% |
Profile
| Aspen Pharmacare Holdings Ltd. manufactures and supplies branded and generic pharmaceutical products. It operates through the following segments: Commercial Pharmaceuticals, Injectables, and Manufacturing. The Commercial Pharmaceuticals segment consists of the following business sub segments: Sterile Focused Brands, which includes the Anaesthetics and Thrombosis portfolios; and Regional Brands, which are products that are managed on a regional basis. The Injectables segment focuses on injectable products which are primarily administered in hospitals and also prescribed and administered by physicians and in a retail pharmacy environment. The Manufacturing segment focuses on the following business sub segments: Active Pharmaceutical Ingredients, which involved in API Chemicals business and non-heparin biochemical API business; Heparin, which refers to the full value chain contribution from all heparin containing products; FDF Steriles, which includes all FDF sterile sales; and FDF Other, which consists of all non-sterile FDF products. The company was founded by Michael Guy Attridge in 1850 and is headquartered in Durban, South Africa. |
| URL | http://www.aspenpharma.com |
| Investor Relations URL | https://www.aspenpharma.com/investor-information/ |
| HQ State/Province | KwaZulu-Natal |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Small Cap Value |
| Next Earnings Release | Sep. 02, 2026 |
| Last Earnings Release | Mar. 03, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Oct. 03, 2025 |
Profile
| Aspen Pharmacare Holdings Ltd. manufactures and supplies branded and generic pharmaceutical products. It operates through the following segments: Commercial Pharmaceuticals, Injectables, and Manufacturing. The Commercial Pharmaceuticals segment consists of the following business sub segments: Sterile Focused Brands, which includes the Anaesthetics and Thrombosis portfolios; and Regional Brands, which are products that are managed on a regional basis. The Injectables segment focuses on injectable products which are primarily administered in hospitals and also prescribed and administered by physicians and in a retail pharmacy environment. The Manufacturing segment focuses on the following business sub segments: Active Pharmaceutical Ingredients, which involved in API Chemicals business and non-heparin biochemical API business; Heparin, which refers to the full value chain contribution from all heparin containing products; FDF Steriles, which includes all FDF sterile sales; and FDF Other, which consists of all non-sterile FDF products. The company was founded by Michael Guy Attridge in 1850 and is headquartered in Durban, South Africa. |
| URL | http://www.aspenpharma.com |
| Investor Relations URL | https://www.aspenpharma.com/investor-information/ |
| HQ State/Province | KwaZulu-Natal |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Small Cap Value |
| Next Earnings Release | Sep. 02, 2026 |
| Last Earnings Release | Mar. 03, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Oct. 03, 2025 |